{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:57:43Z","timestamp":1769151463928,"version":"3.49.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0222095","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T17:25:16Z","timestamp":1567704316000},"page":"e0222095","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vancomycin-associated nephrotoxicity in non-critically ill patients admitted in a Brazilian public hospital: A prospective cohort study"],"prefix":"10.1371","volume":"14","author":[{"given":"Claudmeire Dias Carneiro","family":"de Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":true,"given":"Ana Cristina","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Antonio","family":"de Queiroz Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela Soares Fonseca","family":"Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Henrique","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Eduardo","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandack","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-411X","authenticated-orcid":true,"given":"Maria Auxiliadora Parreiras","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"pone.0222095.ref001","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"C Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0222095.ref002","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.3390\/ijerph120911227","article-title":"Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information Sources","volume":"12","author":"MD Bicalho","year":"2015","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0222095.ref003","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"FR Bruniera","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"pone.0222095.ref004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijid.2017.04.018","article-title":"Evaluation of the variability and safety of serum trough concentrations of vancomycin in patients admitted to the intensive care unit","volume":"60","author":"X Qian","year":"2017","journal-title":"Int J Infect Dis"},{"key":"pone.0222095.ref005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors","volume":"34","author":"CJ Meaney","year":"2014","journal-title":"Pharmacotherapy"},{"key":"pone.0222095.ref006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.medmal.2013.09.011","article-title":"The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia","volume":"43","author":"P Chavanet","year":"2013","journal-title":"Med Mal Infect"},{"key":"pone.0222095.ref007","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"TP Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0222095.ref008","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"SJ van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0222095.ref009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/FTD.0000000000000459","article-title":"Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients","volume":"40","author":"M Chuma","year":"2018","journal-title":"Ther Drug Monit"},{"key":"pone.0222095.ref010","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","article-title":"Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"29","author":"MJ Rybak","year":"2009","journal-title":"Pharmacotherapy"},{"key":"pone.0222095.ref011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"M Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"pone.0222095.ref012","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/aas.12897","article-title":"Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study","volume":"61","author":"V Bakke","year":"2017","journal-title":"Acta Anaesthesiol Scand"},{"key":"pone.0222095.ref013","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5935\/0103-507X.20160071","article-title":"Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients","volume":"28","author":"VY Obara","year":"2016","journal-title":"Rev Bras Ter Intensiva"},{"key":"pone.0222095.ref014","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"TP Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"pone.0222095.ref015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"pone.0222095.ref016","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"pone.0222095.ref017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/kisup.2011.32","article-title":"Section 2: AKI Definition","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"pone.0222095.ref018","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"LD Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"key":"pone.0222095.ref019","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/CCM.0000000000000514","article-title":"Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*","volume":"42","author":"TP Hanrahan","year":"2014","journal-title":"Crit Care Med"},{"key":"pone.0222095.ref020","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"JA Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0222095.ref021","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/cid\/ciy680","article-title":"A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring","volume":"67","author":"X Liang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pone.0222095.ref022","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2147\/IDR.S184897","article-title":"Vancomycin trough level and loading dose","volume":"11","author":"FF Tuon","year":"2018","journal-title":"Infect Drug Resist"},{"key":"pone.0222095.ref023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/IDR.S109485","article-title":"Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience","volume":"9","author":"R Hirano","year":"2016","journal-title":"Infect Drug Resist"},{"key":"pone.0222095.ref024","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"K Matsumoto","year":"2013","journal-title":"J Infect Chemother"},{"key":"pone.0222095.ref025","doi-asserted-by":"crossref","first-page":"e99044","DOI":"10.1371\/journal.pone.0099044","article-title":"Guidelines for therapeutic drug monitoring of vancomycin: a systematic review","volume":"9","author":"ZK Ye","year":"2014","journal-title":"PLoS One"},{"key":"pone.0222095.ref026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijantimicag.2017.08.012","article-title":"Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies","volume":"51","author":"JN O\u2019Donnell","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0222095.ref027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime","volume":"64","author":"B Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0222095.ref028","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime","volume":"34","author":"DM Gomes","year":"2014","journal-title":"Pharmacotherapy"},{"key":"pone.0222095.ref029","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1060028018757497","article-title":"Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin\/Tazobactam: A Prospective","volume":"52","author":"BP Mullins","year":"2018","journal-title":"Multicenter Study. Ann Pharmacother"},{"key":"pone.0222095.ref030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijantimicag.2018.03.024","article-title":"Nephrotoxicity of piperacillin\/tazobactam combined with vancomycin: should it be a concern?","volume":"52","author":"C Balci","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0222095.ref031","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mayocp.2018.08.034","article-title":"Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis","volume":"94","author":"R Zonozi","year":"2019","journal-title":"Mayo Clin Proc"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0222095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T17:12:46Z","timestamp":1664298766000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0222095"}},"subtitle":[],"editor":[{"given":"Chiara","family":"Lazzeri","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0222095","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}